Latest News - Johnson & Johnson
Top Corporates Hub
Johnson & Johnson
Is Johnson & Johnson’s (JNJ) Recent Rally Still Leaving the Stock Undervalued?
24.12.2025 01:12
Johnson & Johnson (JNJ) has been quietly grinding higher, with shares up sharply over the past year even after a recent pullback. Investors are now asking whether this run still leaves meaningful upside. See our latest analysis for Johnson & Johnson. Momentum still looks constructive here, with the share price up meaningfully over the past year and a strong 90 day share price return of 16.46 percent supporting a 1 year total shareholder return of 45.41 percent. If J&J’s steady climb has you...
Over $1.5 Billion Baltimore Verdict Holds Johnson & Johnson Liable Over Iconic Baby Powder
23.12.2025 04:15
BALTIMORE, December 23, 2025--A Baltimore city jury has returned a verdict in favor of Cherie A. Craft, awarding her over $1.5 billion after finding that Johnson & Johnson and its subsidiaries exposed her to asbestos through talc-based personal care products and caused her to develop peritoneal malignant mesothelioma, an incurable cancer. The verdict is believed to be the largest ever returned against Johnson & Johnson for a single plaintiff.
What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report
22.12.2025 09:30
Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
18.12.2025 13:00
Johnson & Johnson (NYSE: JNJ) – Today, Johnson & Johnson MedTech, a leader in neurovascular care, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for embolization of the middle meningeal artery (MMA) for the treatment of symptomatic subacute and chronic Subdural Hematoma (cSDH) as an adjunct to surgery.
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
18.12.2025 12:00
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for patients with epidermal growth factor receptor (EGFR)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).1 RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) and represents the
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
18.12.2025 02:09
Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ stock is a Buy.
LENZ Therapeutics: Was That A Market Overreaction?
17.12.2025 09:02
LENZ Therapeutics, Inc.'s VIZZ shows promise despite a recent adverse event. Click for LENZ investment insights, risks, and growth potential in the eye care market.
Johnson & Johnson: Quality Compounding, Valuations Now Do The Heavy Lifting
16.12.2025 03:54
Johnson & Johnson's organic growth and margin expansion remain moderate. Read why I would not add fresh capital to JNJ stock for now.
J&J gains label expansion approval for Akeega in mCSPC
15.12.2025 18:10
Akeega’s indicated usage now spans across mCSPC and mCRPC, widening the drug’s future market potential.
Johnson & Johnson Remains Stable With Modest Growth Potential, BofA Says
15.12.2025 16:49
Johnson & Johnson (JNJ) remains a stable, relatively low-risk stock, though its upside appears limit
Dow Jones Industrial Average's top-performing stocks of 2025
15.12.2025 16:00
Ahead of the new year, Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at some of the Dow Jones Industrial Average's (^DJI) best performers in 2025: Caterpillar (CAT), Goldman Sachs (GS), Johnson & Johnson (JNJ), and IBM (IBM). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
15.12.2025 15:49
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD
15.12.2025 14:50
AC Immune receives a "Buy" rating, driven by positive phase 2 VacSYn trial results for ACI-7104.056 in early Parkinson's Disease. Click to read why ACIU is a Buy.
MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH
15.12.2025 14:50
Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
Johnson & Johnson (JNJ) Is Considered a Good Investment by Brokers: Is That True?
15.12.2025 14:30
Based on the average brokerage recommendation (ABR), Johnson & Johnson (JNJ) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Take the Zacks Approach to Beat the Markets: Liquidia, Western Digital & Johnson & Johnson in Focus
15.12.2025 14:06
Liquidia shares have surged 43.9% since an October upgrade, as Zacks highlights stock wins and portfolio results despite a volatile market.
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
15.12.2025 13:30
Link Cell Therapies ("Link"), an oncology cell therapy company, today announced its official launch from stealth with a $60 million Series A financing that was led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. , with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and other new strategic and financial investors.